Page data last changed: . Registry refreshes and identity assessments are separate from scientific content review.
A soluble decoy receptor designed to intercept myostatin before it signals.
Also known as: ActRIIB-IgG1 · ramatercept
Part of the Growth hormone & IGF peptides cluster
Overview
ACE-031 is an engineered decoy receptor made by fusing the extracellular domain of the activin receptor type IIB (ActRIIB) to an IgG1 Fc fragment. It binds myostatin and related ligands to block their signaling. It is investigational, its clinical development was halted, and it is not approved; this page is educational only.
Source & context
Biological / chemical source: Recombinant fusion of the ActRIIB extracellular domain with an IgG1 Fc
Primary research or clinical context: Investigational compound; development halted, not approved
Decoy-receptor mechanism
Myostatin normally binds ActRIIB on muscle to restrain growth. ACE-031 presents a soluble copy of the receptor's ligand-binding domain, so it captures myostatin and related TGF-beta ligands in circulation before they reach cell-surface receptors. The Fc fusion prolongs its half-life, a common biologic-engineering approach.
Trial history and status
ACE-031 was tested in a randomized trial in boys with Duchenne muscular dystrophy (NCT01099761), which was stopped early based on preliminary safety findings. It never reached approval and remains investigational. This summary describes the molecule and its history for education and makes no efficacy or safety claims.
Structure & chemistry
Molecular identity & reference confidence
Reference mass unavailable
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- ACE-031 (source record; form not independently established)
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
Clinical development snapshot
ClinicalTrials.gov lists 4 registered studies with “ACE-031” as an intervention (snapshot 2026-09-06). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT01099761 | Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy | Phase 2 | terminated | 2022-10-13 |
| NCT01239758 | Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy | Phase 2 | terminated | 2013-02-01 |
| NCT00952887 | A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women | Phase 1 | completed | 2011-03-23 |
| NCT00755638 | A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmeno | Phase 1 | completed | 2009-07-14 |
FAQ about ACE-031
What is ACE-031?+
ACE-031 is an engineered decoy receptor made by fusing the extracellular domain of the activin receptor type IIB (ActRIIB) to an IgG1 Fc fragment. It binds myostatin and related ligands to block their signaling. It is investigational, its clinical development was halted, and it is not approved; this page is educational only.
What Canadian product status is recorded for ACE-031?+
Canadian product status for ACE-031 has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of ACE-031?+
ACE-031 is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.
Related peptides
References & further reading
- 1.Reichel et al. (2025). Gel Electrophoretic Detection of Black Market ACE-031. Drug Test Anal
- 2.Attie et al. (2013). A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve
- 3.Cadena et al. (2025). ACE-031, a Soluble Activin Type IIB Receptor, Increases Muscle Mass and Strength in the Common Marmoset (Callithrix jacchus). bioRxiv
- 4.Campbell et al. (2017). Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve
- 5.Cadena et al. (2026). ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus). PLoS One
- 6.ClinicalTrials.gov — ACE-031 in Duchenne muscular dystrophy (NCT01099761)
- 7.Wikipedia — Decoy receptors (ACE-031)